Antibody against tumor specific antigen as target
AssigneeSankyo Company, Limited
InventorsKimihisa Ichikawa, Shu Takahashi, Toshinori Agatsuma, Keisuke Fukuchi, Takehiro Hirai
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.
Claims18
1-27. (canceled)
An antibody which a) specifically binds to a human oculospanin protein selected from at least one member of the group consisting of SEQ ID NO:2 and SEQ ID NO:4, and b) has cytotoxic activity against a cell expressing said oculospanin protein.
A method of detecting cancer comprising:
- a) measuring the amount of nucleic acid encoding oculospanin from a human test sample;
- b)measuring the amount of nucleic acid encoding oculospanin from a human healthy sample;
- and
- c) comparing the difference in said amounts to determine the presence of cancer in said test sample.
A method of detecting cancer comprising:
- a) measuring the amount of oculospanin protein from a human test sample;
- b )measuring the amount of oculospanin protein from a human healthy sample;
- and
- c) comparing the difference in said amounts to determine the presence of cancer in said test sample.
A detection kit for cancer comprising an oligonucleotide primer of from about 15 to about 30 bases in length that specifically binds to SEQ ID NO:1 or its complement under high stringency conditions.
A detection kit for cancer comprising an antibody that specifically binds to a human oculospanin protein (SEQ ID NO:2).
A pharmaceutical composition for treating cancer comprising an antibody according to claim 1 and a pharmaceutically acceptable carrier.
A pharmaceutical composition for treating cancer comprising an oligonucleotide having a nucleotide sequence selected from at least one member of the group consisting of a nucleotide sequence complementary to SEQ ID NO:1 and a partial nucleotide sequence complementary to SEQ ID NO:1, and a pharmaceutically acceptable carrier.
A method of inducing cytotoxicity in a cell expressing an oculospanin protein comprising contacting said cell with an antibody which specifically binds to a human oculospanin protein selected from at least one member of the group consisting of SEQ IDNO:2 and SEQ ID NO:4.
A method of screening for compounds that induce cytotoxicity in a cell expressing an oculospanin protein comprising contacting said cell with a compound and assaying for cytotoxicity.
A method of inducing cytotoxicity in a cell by specifically binding a compound to a cell expressing a human oculospanin protein selected from at least one member of the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
Dependencies are inferred from the claim text.